What is HC Wainwright's Forecast for Precigen Q1 Earnings?

Precigen, Inc. (NASDAQ:PGEN - Free Report) - HC Wainwright lowered their Q1 2025 earnings per share (EPS) estimates for Precigen in a research report issued on Thursday, March 20th. HC Wainwright analyst S. Ramakanth now expects that the biotechnology company will post earnings per share of ($0.08) for the quarter, down from their prior forecast of ($0.04). HC Wainwright currently has a "Buy" rating and a $6.00 target price on the stock. The consensus estimate for Precigen's current full-year earnings is ($0.32) per share. HC Wainwright also issued estimates for Precigen's Q2 2025 earnings at ($0.08) EPS, Q3 2025 earnings at ($0.07) EPS, Q4 2025 earnings at ($0.07) EPS, FY2025 earnings at ($0.29) EPS and FY2026 earnings at ($0.06) EPS.

Separately, JMP Securities restated a "market outperform" rating and set a $5.00 price objective on shares of Precigen in a research report on Tuesday, January 14th. One analyst has rated the stock with a sell rating and four have assigned a buy rating to the stock. According to MarketBeat.com, the stock presently has a consensus rating of "Moderate Buy" and an average price target of $7.00.

Precigen Stock Performance

Shares of PGEN stock traded up $0.03 during midday trading on Monday, hitting $1.64. 1,423,186 shares of the company were exchanged, compared to its average volume of 1,178,785. Precigen has a 52 week low of $0.65 and a 52 week high of $2.17. The firm has a market capitalization of $482.23 million, a P/E ratio of -2.98 and a beta of 1.58. The firm's 50 day moving average price is $1.65 and its two-hundred day moving average price is $1.17.

Remove Ads

Precigen (NASDAQ:PGEN - Get Free Report) last released its quarterly earnings data on Wednesday, March 19th. The biotechnology company reported ($0.04) EPS for the quarter, topping analysts' consensus estimates of ($0.06) by $0.02. The firm had revenue of $1.19 million during the quarter, compared to analysts' expectations of $1.30 million. Precigen had a negative net margin of 3,521.68% and a negative return on equity of 123.06%.

Hedge Funds Weigh In On Precigen

Several institutional investors and hedge funds have recently modified their holdings of the business. Charles Schwab Investment Management Inc. boosted its holdings in Precigen by 11.6% in the 3rd quarter. Charles Schwab Investment Management Inc. now owns 1,222,850 shares of the biotechnology company's stock valued at $1,158,000 after purchasing an additional 127,467 shares during the period. FMR LLC raised its position in shares of Precigen by 26.4% in the third quarter. FMR LLC now owns 345,204 shares of the biotechnology company's stock valued at $327,000 after buying an additional 72,033 shares in the last quarter. HighTower Advisors LLC boosted its stake in shares of Precigen by 186.8% in the third quarter. HighTower Advisors LLC now owns 192,144 shares of the biotechnology company's stock valued at $179,000 after buying an additional 125,145 shares during the period. Stifel Financial Corp boosted its stake in shares of Precigen by 94.9% in the third quarter. Stifel Financial Corp now owns 32,200 shares of the biotechnology company's stock valued at $30,000 after buying an additional 15,680 shares during the period. Finally, State Street Corp grew its position in Precigen by 1.0% during the third quarter. State Street Corp now owns 2,872,064 shares of the biotechnology company's stock worth $2,720,000 after buying an additional 29,253 shares in the last quarter. 33.51% of the stock is currently owned by institutional investors and hedge funds.

About Precigen

Precigen, Inc operates as a discovery and clinical-stage biopharmaceutical company that develops gene and cell therapies using precision technology to target diseases in therapeutic areas of immuno-oncology, autoimmune disorders, and infectious diseases. It operates through two segments, Biopharmaceuticals and Exemplar.